A multicenter, double-blind, randomized, placebo-controlled, phase II trial in patients with thyroid eye disease showed a significant response to teprotumumab vs placebo.1
Dr. Douglas concluded that the results confirmed teprotumumab to be highly effective in reducing proptosis, supportin…